PREFERENTIAL INHIBITION OF INDUCIBLE NITRIC-OXIDE SYNTHASE BY EBSELEN

被引：53

作者：

HATTORI, R ^{[1
]}

INOUE, R ^{[1
]}

SASE, K ^{[1
]}

EIZAWA, H ^{[1
]}

KOSUGA, K ^{[1
]}

AOYAMA, T ^{[1
]}

MASAYASU, H ^{[1
]}

KAWAI, C ^{[1
]}

SASAYAMA, S ^{[1
]}

YUI, Y ^{[1
]}

机构：

[1] DAIICHI PHARMACEUT CO LTD,CHUO KU,TOKYO 103,JAPAN

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION | 1994年 / 267卷 / 02期

关键词：

EBSELEN; NITRIC OXIDE (NO) SYNTHASE;

D O I：

10.1016/0922-4106(94)90179-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ebselen, 2-phenyl-1,2-benzisoselenazole-3(2H)-one can preferentially inhibit the activity of inducible nitric oxide (NO) synthase with little inhibition of endothelial constitutive NO synthase within a certain concentration range. This suggests that ebselen deserves further in vivo studies to examine its possible application to the therapy of septic shock where inducible NO synthase is responsible for vasodilation.

引用

页码：R1 / R2

页数：2

共 6 条

[1]

MONCADA S, 1993, NEW ENGL J MED, V329, P2002

[2] A NOVEL BIOLOGICALLY-ACTIVE ORGANOSELENIUM COMPOUND .1. GLUTATHIONE PEROXIDASE-LIKE ACTIVITY INVITRO AND ANTIOXIDANT CAPACITY OF PZ-51 (EBSELEN) [J].